MARKET

RKVTF

RKVTF

RAKOVINA THERAPEUTICS INC
OTCPK
0.117
0.000
0.09%
Closed 14:31 02/17 EST
OPEN
0.117
PREV CLOSE
0.117
HIGH
0.117
LOW
0.117
VOLUME
9.00K
TURNOVER
1.05K
52 WEEK HIGH
1.200
52 WEEK LOW
0.065
MARKET CAP
2.48M
P/E (TTM)
-0.2862
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RKVTF last week (0209-0213)?
Weekly Report · 1d ago
Weekly Report: what happened at RKVTF last week (0202-0206)?
Weekly Report · 02/09 10:16
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Barchart · 02/04 03:00
Weekly Report: what happened at RKVTF last week (0126-0130)?
Weekly Report · 02/02 10:16
Weekly Report: what happened at RKVTF last week (0119-0123)?
Weekly Report · 01/26 10:16
Weekly Report: what happened at RKVTF last week (0112-0116)?
Weekly Report · 01/19 10:21
Weekly Report: what happened at RKVTF last week (0105-0109)?
Weekly Report · 01/12 10:21
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
Barchart · 01/08 03:00
More
About RKVTF
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.

Webull offers Rakovina Therapeutics Inc stock information, including OTCPK: RKVTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RKVTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RKVTF stock methods without spending real money on the virtual paper trading platform.